Roche has welcomed MHRA marketing authorisation for Gazyvaro, indicated for adults with moderate to severe, active, autoantibody-positive systemic lupus erythematosus receiving standard therapy.

Gazyva (obinutuzumab) - Roche, Biogen

Sep 23, 2026